JanOne Engages CATO SMS to Assist in the Development of JAN101

JanOne Engages CATO SMS , a World-Leading CRO , to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications

CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients.

In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).

In partnership with CATO SMS , JanOne is currently preparing an investigator-initiated IND package for the FDA, which it expects to submit in the coming month.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.